Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Total Valuation
Capricor Therapeutics has a market cap or net worth of $1.85B. The enterprise value is $1.20B.
Market Cap$1.85B
Enterprise Value$1.20B
Share Statistics
Capricor Therapeutics has 57,510,635 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,510,635
Owned by Insiders0.98%
Owned by Institutions22.25%
Financial Efficiency
Capricor Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -33.10%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-33.10%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-656.52M
Employee Count160
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Capricor Therapeutics is ―. Capricor Therapeutics’s PEG ratio is -0.13.
PE Ratio―
PS Ratio0.00
PB Ratio4.39
Price to Fair Value4.39
Price to FCF-0.02
Price to Operating Cash Flow-22.47
PEG Ratio-0.13
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of 0.00 and earned -105.04M in profits. Earnings per share was -2.26.
Revenue0.00
Gross Profit0.00
Operating Income-108.14M
Pretax Income-105.04M
Net Income-105.04M
EBITDA-108.14M
Earnings Per Share (EPS)-2.26
Cash Flow
In the last 12 months, operating cash flow was -69.81M and capital expenditures -11.72M, giving a free cash flow of -81.54M billion.
Operating Cash Flow-69.81M
Free Cash Flow-81.54M
Free Cash Flow per Share-1.42
Dividends & Yields
Capricor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.53
52-Week Price Change249.78%
50-Day Moving Average27.23
200-Day Moving Average15.43
Relative Strength Index (RSI)59.83
Average Volume (3m)1.56M
Important Dates
Capricor Therapeutics upcoming earnings date is May 20, 2026, After Close (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Capricor Therapeutics as a current ratio of 9.01, with Debt / Equity ratio of 6.85%
Current Ratio9.01
Quick Ratio9.01
Debt to Market Cap<0.01
Net Debt to EBITDA2.47
Interest Coverage Ratio-35.51
Taxes
In the past 12 months, Capricor Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Capricor Therapeutics EV to EBITDA ratio is -9.94, with an EV/FCF ratio of -0.01.
EV to Sales0.00
EV to EBITDA-9.94
EV to Free Cash Flow-0.01
EV to Operating Cash Flow-0.02
Balance Sheet
Capricor Therapeutics has $318.13M in cash and marketable securities with $20.94M in debt, giving a net cash position of $297.18M billion.
Cash & Marketable Securities$318.13M
Total Debt$20.94M
Net Cash$297.18M
Net Cash Per Share$5.17
Tangible Book Value Per Share$6.58
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Capricor Therapeutics is $55.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$55.13
Price Target Upside71.69% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-52.08%
EPS Growth Forecast-69.35%